$ 345.60
Details
The 16-10A1 antibody reacts with CD80 (B7-1). This member of the Ig superfamily, along with CD86 (B7-2), participates in T-cell co-stimulation via interactions with CD28 and CD152 (CTLA-4). CD80 has been reported to be constitutively expressed on dendritic cells, monocytes, and peritoneal macrophages; and it is inducible on B cells by various means, including activation by LPS, IL-4, and the cross-linking of surface Ig. Expression of CD80 has been reported to be greatly enhanced on splenic B cells following activation by LPS, with peak expression occurring between 48 and 72 hours. It has been reported that the activation of purified B cells with LPS can induce CD80 expression in as few as 18 hours. The 16-10A1 antibody has been reported to block binding of CTLA-4 Ig to CD80 and to block T-cell activation by Con A-elicited peritoneal exudate cells and CD80-transfected cell lines. However, 16-10A1 antibody alone is not able to block T-cell activation by antigen-presenting cells. CD86 (B7-2) is an alternate ligand for CD28 and CD152 (CTLA-4). Preliminary reports indicate that the 16-10A1 mAb may block the binding of rat anti-CD80 mAb clone 1G10 (Cat. No. 553368). In addition, it has been reported that the 16-10A1 antibody may cross-react with an activation antigen expressed on IFN-γ-activated alveolar macrophages of the dog. This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
